nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2024-11-3-87-91nodgo-1076Research ArticleРЕЗОЛЮЦИИRESOLUTIONSРезолюция Совета экспертов «Вопросы использования CAR-T-препаратов в терапии В-клеточного острого лимфобластного лейкоза»Resolution of the Council of Experts “Issues of using CAR-T drugs in the treatment of B-cell acute lymphoblastic leukemia”РедакционнаястатьяEditorialArticle2024311020241138791Copyright © Редакционная с., 20242024Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/1076
.
ReferencesHenze G., Stackelberg A., Eckert C. ALL-REZ BFM-The consecutive trials for children with relapsed acute lymphoblastic leukemia. Klin Padiatr. 2013;225 Suppl 1:S73–8. doi: 10.1055/s-0033-1337967.Henze G., Stackelberg A., Eckert C. ALL-REZ BFM-The consecutive trials for children with relapsed acute lymphoblastic leukemia. Klin Padiatr. 2013;225 Suppl 1:S73–8. doi: 10.1055/s-0033-1337967.Moricke A., Zimmermann M., Reiter A., Henze G., Schrauder A. Gadner H., Ludwig W.D., Ritter J., Harbott J., Mann G., Klingebiel T., Zintl F., Niemeyer C., Kremens B., Niggli F., Niethammer D., Welte K., Stanulla M., Odenwald E., Riehm H., Schrappe M. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–84. doi: 10.1038/leu.2009.257.Moricke A., Zimmermann M., Reiter A., Henze G., Schrauder A. Gadner H., Ludwig W.D., Ritter J., Harbott J., Mann G., Klingebiel T., Zintl F., Niemeyer C., Kremens B., Niggli F., Niethammer D., Welte K., Stanulla M., Odenwald E., Riehm H., Schrappe M. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–84. doi: 10.1038/leu.2009.257.Oskarsson T., Soderholl S., Arvidson J., Forestier E., Montgomery S., Bottai M., Lausen B., Carlsen N., Hellebostad M., Lähteenmäki P., Saarinen-Pihkala U.M., Jónsson Ó.G., Heyman M.; Nordic Society of Paediatric Haematology and Oncology (NOPHO). ALL relapse working group Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101(1):68–76. doi: 10.3324/haematol.2015.131680.Oskarsson T., Soderholl S., Arvidson J., Forestier E., Montgomery S., Bottai M., Lausen B., Carlsen N., Hellebostad M., Lähteenmäki P., Saarinen-Pihkala U.M., Jónsson Ó.G., Heyman M.; Nordic Society of Paediatric Haematology and Oncology (NOPHO). ALL relapse working group Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101(1):68–76. doi: 10.3324/haematol.2015.131680.Parker C., Waters R., Leighton C., Hancock J., Sutton R., Moorman A.V., Ancliff P., Morgan M., Masurekar A., Goulden N., Green N., Révész T., Darbyshire P., Love S., Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomized trial. Lancet. 2010;376(9757):2009–17. doi: 10.1016/S0140-6736(10)62002-8.Parker C., Waters R., Leighton C., Hancock J., Sutton R., Moorman A.V., Ancliff P., Morgan M., Masurekar A., Goulden N., Green N., Révész T., Darbyshire P., Love S., Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomized trial. Lancet. 2010;376(9757):2009–17. doi: 10.1016/S0140-6736(10)62002-8.Ko R.H., Ji L., Barnette P., Bostrom B., Hutchinson R., Raetz E., Seibel N.L., Twist C.J., Eckroth E., Sposto R., Gaynon P.S., Loh M.L. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648–54. doi: 10.1200/JCO.2009.22.2950.Ko R.H., Ji L., Barnette P., Bostrom B., Hutchinson R., Raetz E., Seibel N.L., Twist C.J., Eckroth E., Sposto R., Gaynon P.S., Loh M.L. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648–54. doi: 10.1200/JCO.2009.22.2950.Клинические рекомендации «Острый лимфобластный лейкоз», ID: 529. [Электронный ресурс]: URL: https://cr.minzdrav.gov.ru/recomend/529?ysclid=lz7apqka7c882238403 (дата обращения 20.05.2024).Clinical guidelines “Acute lymphoblastic leukemia”, ID: 529. [Electronic resource]: URL: https://cr.minzdrav.gov.ru/recom end/529?ysclid=lz7apqka7c882238403 (appeal date 20.05.2024). (In Russ.).Клинические рекомендации «Острые лимфобластные лейкозы», ID: 496. [Электронный ресурс]: URL: https://cr.minzdrav.gov.ru/recomend/496_1 (дата обращения 20.05.2024).Clinical guidelines “Acute lymphoblastic leukemia”, ID: 496. [Electronic resource]: URL: https://cr.minzdrav.gov.ru/recomend/496_1 (appeal date 20.05.2024). (In Russ.).Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P., Verneris M.R., Stefanski H.E., Myers G.D., Qayed M., de Moerloose B., Hiramatsu H., Schlis K., Davis K.L., Martin P.L., Nemecek E.R., Yanik G.A., Peters C., Baruchel A., Boissel N., Mechinaud F., Balduzzi A., Krueger J., June C.H., Levine B.L., Wood P., Taran T., Leung M., Mueller K.T., Zhang Y., Sen K., Lebwohl D., Pulsipher M.A., Grupp S.A. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48. doi: 10.1056/nejmoa1709866.Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P., Verneris M.R., Stefanski H.E., Myers G.D., Qayed M., de Moerloose B., Hiramatsu H., Schlis K., Davis K.L., Martin P.L., Nemecek E.R., Yanik G.A., Peters C., Baruchel A., Boissel N., Mechinaud F., Balduzzi A., Krueger J., June C.H., Levine B.L., Wood P., Taran T., Leung M., Mueller K.T., Zhang Y., Sen K., Lebwohl D., Pulsipher M.A., Grupp S.A. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48. doi: 10.1056/nejmoa1709866.Shah B.D., Ghobadi A., Oluwole O.O., Logan A.C., Boissel N., Cassaday R.D., Leguay T., Bishop M.R., Topp M.S., Tzachanis D., O’Dwyer K.M., Arellano M.L., Lin Y., Baer M.R., Schiller G.J., Park J.H., Subklewe M., Abedi M., Minnema M.C., Wierda W.G., DeAngelo D.J., Stiff P., Jeyakumar D., Feng C., Dong J., Shen T., Milletti F., Rossi J.M., Vezan R., Masouleh B.K., Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8.Shah B.D., Ghobadi A., Oluwole O.O., Logan A.C., Boissel N., Cassaday R.D., Leguay T., Bishop M.R., Topp M.S., Tzachanis D., O’Dwyer K.M., Arellano M.L., Lin Y., Baer M.R., Schiller G.J., Park J.H., Subklewe M., Abedi M., Minnema M.C., Wierda W.G., DeAngelo D.J., Stiff P., Jeyakumar D., Feng C., Dong J., Shen T., Milletti F., Rossi J.M., Vezan R., Masouleh B.K., Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8.Гаврилина О.А., Галстян Г.М., Щекина А.Е., Котова Е.С., Масчан М.А., Троицкая В.В., Королева Д.А., Звонков Е.Е., Фидарова З.Т., Васильева В.А., Паровичникова Е.Н. Терапия Т-клетками с химерным антигенным рецептором взрослых больных В-клеточными лимфопролиферативными заболеваниями. Гематология и трансфузиология. 2022;67(1):8–28. doi: 10.35754/02345730-2022-67-1-8-28.Gavrilina O.A., Galstyan G.M., Shchekina A.E., Kotova E.S., Maschan M.A., Troitskaya V.V., Koroleva D.A., Zvonkov E.E., Fidarova Z.T., Vasilyeva V.A., Parovichnikova E.N. Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology. 2022;67(1):8–28. (In Russ.). doi: 10.35754/02345730-2022-67-1-8-28.June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. doi: 10.1126/science.aar6711.June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. doi: 10.1126/science.aar6711.FDA approval brings first gene therapy to the United States [news release] Silver Spring, MD: US Food and Drug Administration [Electronic resource]: URL: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm (appeal date 20.05.2024).FDA approval brings first gene therapy to the United States [news release] Silver Spring, MD: US Food and Drug Administration [Electronic resource]: URL: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm (appeal date 20.05.2024).
The authors declare that there are no conflicts of interest present.